News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2020 FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease Todd Neale November 16, 2020
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News AHA 2012 AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community Jason Kahn November 11, 2012